Conference Reports for NATAP

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom  April 9-13 Back

Ledipasvir/Sofosbuvir Retreating Prior Failures Phase 3       EASL: Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)   EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)   EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13